KB103 is an internally generated modified HSV-1 based gene therapy candidate engineered with a COL7A1 gene construct to treat Dystrophic Epidermolysis Bullosa (DEB) Therapeutic candidate formulated into a topical gel for direct application onto skin PITTSBURGH , March 27, 2018 (GLOBE NEWSWIRE) --

IND for KB103 to treat Dystrophic Epidermolysis Bullosa (DEB) to be filed in March 2018 IND for KB105 to treat Lamellar Ichthyosis to be filed in Q4 2018 Company was granted composition of matter and method of use patent by USPTO in January 2018 GMP facility for production of KB103 and pipeline

PITTSBURGH , March 05, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ:KRYS), a gene therapy company advancing “off-the-shelf,” treatments for dermatological diseases, today announced that Krish Krishnan , Chief Executive Officer, will present a corporate overview and business update at the

PITTSBURGH , Jan. 16, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ:KRYS), a gene therapy company advancing “off-the-shelf,” treatments for dermatological diseases, today announced that the United States Patent Office (USPTO) has granted U.S. Patent No.

PITTSBURGH , Nov. 13, 2017 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ:KRYS), a gene therapy company advancing “off-the-shelf,” topical and intra-dermal treatments for dermatological diseases, today reported financial results for the third quarter ended September 30, 2017 , and provided an

PITTSBURGH, Pa. , Nov. 07, 2017 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq:KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that the U.S.

PITTSBURGH, Nov. 03, 2017 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq:KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that it has received an equity-based award totaling $770,000

PITTSBURGH , Sept. 22, 2017 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (“Krystal”) (NASDAQ:KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced the closing of its initial public offering of

PITTSBURGH , Sept. 21, 2017 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (“Krystal”)(Nasdaq:KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced a presentation of preclinical data assessing the

PITTSBURGH, Pa. , Sept. 19, 2017 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (“Krystal”), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced the pricing of its initial public offering.